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Background: Despite the presence of existing guidelines, underuse of inhaled corticosteroids 
(ICSs) still exists among patients with persistent asthma in the United States. Inappropriate 
utilization of asthma medications has been attributed as one of the reasons for the significant 
economic burden due to asthma.
Objectives: To determine the demographic factors predicting patient-reported use of ICSs 
among patients with asthma.
Methods: The study utilized data from the 4-state sample of the National Asthma Survey 
(NAS), sponsored by the National Center for Environmental Health (NCEH), Centers for   Disease 
Control and Prevention (CDC). The study population consisted of patients with persistent 
asthma as defined by National Heart, Lung, and Blood Institute (NHLBI) guidelines. Frequency 
distributions were made to characterize the study population. Logistic regression analysis was 
carried out to determine the odds of reported use of ICSs across various demographic variables 
(age, gender, race, income level, insurance coverage, and disease severity). Data were analyzed 
using SAS v9.0 software.
Results: Underutilization of ICSs was found to exist in the patients with asthma, as more than 
half of the study population (52.8%, n = 304) did not report the use of ICSs. African American 
patients were found to have much lower odds for use of ICSs (odds ratio [OR] = 0.495;   confidence 
interval [CI], 0.248–0.987) when compared with whites. Insured patients had significantly higher 
odds for the use of ICSs (OR = 2.378; CI, 1.106–5.110) compared with uninsured patients. 
The findings held true even after adjusting for other demographic factors.
Conclusion: Underuse of ICSs continues to be a problem in patients with asthma. Vulnerable 
populations identified in this study are targeted for the use of ICSs. The importance of adherence 
to treatment and use of ICSs is an issue that needs to be addressed.
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Introduction
Asthma affects an estimated 300 million people of all ages and ethnic backgrounds 
worldwide and remains a source of significant morbidity and mortality despite 
  well-established guidelines for proper management.1 Consequently, poor control of 
this disease is posing a significant economic burden on society. Utilization costs attrib-
uted to asthma rank amongst the highest for chronic diseases.2 These costs have been 
increasing despite the presence of existing guidelines and effective preventive therapy.2 
Currently, asthma management is governed by the guidelines of US National Heart, 
Lung, and Blood Institute (NHLBI) titled Expert Panel Report-3 (EPR-3).3 Accord-
ing to these guidelines, asthma control is defined as the degree to which symptoms, 
impairment, and risk are reduced and the degree to which the therapy goals are met.3 Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Based on this definition, more than half of the US population 
with asthma have been classified as having uncontrolled asth-
ma.4 It is also one of the main causes for the increasing expen-
diture on asthma medication among patients with persistent 
asthma. This poor control is often attributed to inappropriate 
utilization of asthma medications. Medications such as inhaled 
corticosteroids (ICSs) play an important role in controlling 
inflammation and minimizing asthma exacerbations, which 
ultimately reduce utilization of the use of other health-care 
resources and related costs.
The guidelines describe ICSs as the preferred long-term 
therapy choice in children and adults. ICSs have shown to 
be well tolerated and safe at recommended doses.3 Evidence 
in the literature supports the benefits of ICSs in decreasing 
symptoms and reducing risk of death. Despite evidence 
in favor of the use of ICSs, recent studies have found that 
underuse of ICSs is prevalent among patients with persis-
tent asthma.5,6 These studies suggest that the underuse of 
  long-acting controller drugs may worsen asthma control in 
the long run. In turn, this leads to an increase in health-care 
utilization by the patient in the form of increased physician 
visits and more frequent hospital admissions for asthma-
related complications.6 Therefore, inappropriate use of 
medications and failure to adhere to therapy have been found 
to lead to undesirable consequences for the patients.7
The economic costs and outcomes, such as   hospitalization 
and emergency room (ER) visits, attributed to asthma have been 
correlated with not only the severity of the disease but also the 
additional factors such as demographic   characteristics.2 Studies 
have shown that female patients tend to have higher costs for 
asthma compared with male patients.8 Race-wise comparisons 
have shown that whites tend to have significantly more primary 
care visits, while African Americans had significantly more 
ER visits.9,10 Therefore, demographic characteristics, such as 
age, race, and gender, have a role in determining the costs of 
medication for the disease. However, critical gaps exist in the 
current literature about disparities at the asthma treatment level, 
particularly regarding the appropriate utilization of asthma 
medications in a diverse patient population.
Based on the evidence present in the literature, the 
researchers hypothesize that demographic disparities exist 
in utilizing ICSs amongst patients with asthma. The issue of 
disparities in the use of ICSs has not been addressed in lit-
erature that studied a large population. Identifying disparities 
will help in directing policy changes and improve patient care 
in the population with asthma. Improving care and adherence 
will consequently increase the quality and effectiveness of 
asthma management. The primary objective of this study 
was to describe reported use of ICSs among patients with 
persistent asthma and identify any demographic disparities 
in reporting such use among the study population.
Methods
The study used a retrospective, cross-sectional research 
design. This study was approved by the University of Toledo 
Institutional Review Board.
Data source
The data for this study were collected from the National 
Asthma Survey (NAS). NAS is sponsored by the National 
Center for Environmental Health (NCEH), Centers for Dis-
ease Control and Prevention (CDC). It examines the health, 
socioeconomic, behavioral, and environmental predictors 
that relate to better control of asthma.11 The researchers 
used the data of 4-state study, which was conducted as a 
part of NAS in Alabama, California, Illinois, and Texas. 
NAS was carried out using random-digit-dial telephone 
survey method, and the data were collected by the State 
and Local Area Integrated Telephone Survey (SLAITS) of 
the National Center for Health Statistics (NCHS), CDC. 
The survey contains approximately 160 questions, 114 of 
which pertain to asthma and the rest are related to survey 
eligibility and demographics. The 4-state survey was car-
ried out only for those respondents who were screened as 
being asthma positive. The participants of the study included 
children aged 0–17 years and adults older than 18 years. If 
the selected household member was a child younger than 18 
years, the questions were addressed to an adult of the house-
hold who was knowledgeable about the child’s health. The 
4-state study was carried out from March 1, 2003, through 
March 10, 2004, and a total of 5,741 detailed interviews 
were completed during this period. The response rate for 
the survey, as reported by the Council of American Survey 
Research Organizations, was 48.5%.12
inclusion criteria
Guidelines recommend daily use of ICSs in patients with 
  persistent asthma; therefore, the study population was 
restricted to patients with persistent asthma. Patients with 
persistent asthma were identified based on the symptoms 
reported by them. According to NHLBI guidelines, asthma 
symptoms experienced at least 2 times a week during the 
day along with at least 2 times during the night characterize 
patients with persistent asthma. After selecting the patients 
with persistent asthma, they were further screened to identify 
those (or parents in case of children) who reported receiving Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
103
Disparities in the patient-reported use of inhaled corticosteroids
all the medications available at the time of their interview. 
Response to the survey question “Am I correct that you have 
all the medications?” helped to determine such patients. 
Finally, the survey respondents who had missing values for 
race and ethnicity variables were excluded from the final 
sample.
Dependent and independent variables
The dependent variable for this study was the reported use 
of ICSs. A comprehensive record on the use of medication 
was available in the database. After analyzing these records, 
patients who reported having at least one of the available ICSs 
were identified and categorized as ICS users, and others were 
categorized as non-ICS users. Independent variables used in 
the analysis included demographic characteristics, such as 
age, race, gender, ethnicity, and income level. Race was cat-
egorized into white, black, and other minorities. Income level 
was categorized by the patient’s annual income of ,20,000, 
20,000–34,999, 35,000–54,999, and .55,000. Other than 
these variables, insurance status and asthma severity were 
also included as independent variables. To categorize patients 
based on asthma severity levels, symptom scoring system 
of National Asthma Education and   Prevention Program 
(NAEPP) was used. Based on the symptoms   experienced, 
patients were categorized into mild (.2 d/wk daytime symp-
toms and 3–4/mo nighttime symptoms), moderate (daytime 
symptoms experienced daily and .4/mo nighttime symp-
toms), and severe (daytime and nighttime symptoms experi-
enced daily). Insurance status was obtained from the survey 
data, and patients were categorized as insured or uninsured 
depending upon their response.
statistical analysis
Chi-square test was used to determine if there are any demo-
graphic differences concerning the reported use of ICSs. 
Patients were stratified into ICS users and non-ICS users, and 
differences with respect to demographic variables and other 
characteristics were determined. A logistic   regression model 
was built to determine the odds of reported use of ICSs adjusted 
for independent variables. Results were weighted to the total 
population of 4 states using the sample weights provided by 
NAS. To account for the   complex survey design, stratum and 
cluster variables were also included in the analysis. It also 
incorporated adjustments for multiple-telephone   households, 
nonresponse unit, and noncoverage of   nontelephone house-
holds and adjustments to known   population-control estimates.3 
SAS 9.1 software (SAS Institute, Cary, North Carolina, USA) 
was used to analyze the data.
Results
The total number of unweighted survey respondents was 
5,741. The sample for analysis was derived from this 
unweighted population based on the inclusion criteria. After 
applying the inclusion criteria, 576 participants met all 
the requirements for this study. The 4-state samples were 
nearly evenly distributed (Table 1) among these 4 states, 
with the maximum number of patients being from Alabama 
(31.8%). The final sample consisted of more female patients 
Table 1 Unweighted sample distribution
Variable Frequency (%)
Race
  Whites 387 (67.2)
  African Americans 114 (19.8)
  Others 75 (13.0)
  Total 576 (100.0)
Ethnicity
  hispanics 72 (12.5)
  non-hispanics 504 (87.5)
  Total 576 (100.0)
Gender
  Female 373 (64.8)
  Male 203 (35.2)
  Total 576 (100.0)
Age group
  Adults ($18 y) 411 (71.4)
  child (,18 y) 165 (28.6)
  Total 576 (100.0)
Insurance
  Yes 498 (86.5)
  no 78 (13.5)
  Total 576 (100.0)
Disease severity
  Mild 294 (51.0)
  Moderate 92 (16.0)
  severe 190 (13.0)
  Total 576 (100.0)
State
  california 133 (23.1)
  illinois 121 (21.0)
  Alabama 187 (32.5)
  Texas 135 (23.4)
  Total 576 (100.0)
Income category
  Annual income
  ,20,000 165 (28.6)
    20,000–34,999 112 (19.4)
    35,000–54,999 84 (14.6)
  .55,000   157 (27.3)
  Missing 58 (10.1)
  Total 576 (100.0)
Inhaled corticosteroids
  no 304 (52.8)
  Yes 272 (47.2)
  Total 576 (100.0)Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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(64.8%) than male patients (35.1%), and a majority of the 
patients were adults (71.4%). Because of the oversampling 
performed, the African American population (19.8%) was 
significantly less, whereas whites (67.2%) formed the 
  majority of the population (Table 1).
Overall, patient-reported use of ICSs was low, with only 
272 (47.2%) patients reporting its use (Table 1). With respect 
to the use of ICSs, Chi-square tests showed significant differ-
ence in race and insurance categories (Table 2). Whites were 
significantly more likely to report ICS usage when compared 
with African Americans or other races (P , 0.05). Patients hav-
ing some form of health insurance were more likely to report 
ICS usage compared with uninsured patients (P , 0.05). No 
significant differences were found for ethnicity, disease sever-
ity, state of residence, income level, age group, or gender.
Results of the logistic regression analysis are reported in 
Table 3. Confirming the results from Chi-square test, regres-
sion analysis showed decreased odds of reported use of ICSs 
among African Americans and uninsured patients in the study 
population. Compared with whites, African Americans had 
significantly decreased odds of reported use of ICSs (odds 
ratio [OR] = 0.495; confidence interval [CI], 0.248–0.987). 
Increased odds for the use of ICSs were also found for insured 
patients (OR = 2.378; CI, 1.106–5.110) compared with 
uninsured patients. In the case of all remaining independent 
variables, no significant difference was observed in terms of 
reported use of ICSs.
Discussion
Our study showed that underuse of ICSs continues to be 
a problem in patients with asthma. More than half of our 
study population did not report the use of ICSs; this issue 
was more severe for minorities and the uninsured population. 
This underuse not only makes the control of disease difficult 
but also increases the health-care expenditure. Colice et al13 
had shown that hospitalizations and ER visits for infrequent 
ICS users were significantly more when compared with 
  consistent users. Despite the wealth of literature highlighting 
the importance of ICSs, the problem still exists as seen in our 
study, and it needs attention by policy makers.
Further, the findings of our study indicate the disparities in 
reported use of ICSs in study population. The primary differ-
ence was found on the basis of race, and African   Americans 
Table  2  Use  of  inhaled  corticosteroids  and  demographic 
characteristics
Characteristic Inhaled corticosteroid use P value
Yes No
Race
  Whites 51.29 48.71 ,0.05
  African Americans 32.68 67.32 –
  Others 36.72 63.28 –
Ethnicity
  hispanics 46.80 53.20 0.761
  non-hispanics 44.11 55.89 –
Insurance
  Yes 46.86 53.14 ,0.05
  no 28.64 71.36 –
Disease severity
  Mild 41.10 58.90 0.398
  Moderate 44.54 55.46 –
  severe 50.24 49.76 –
State
  Alabama 43.36 56.64 0.620
  california 41.96 58.04 –
  illinois 46.94 53.06 –
  Texas 48.86 51.14 –
Income category
  Annual income
  ,20,000 44.51 55.49 0.784
    20,000–34,999 40.63 59.37 –
    35,000–54,999 50.80 49.20 –
  .55,000 46.96 53.04 –
  Missing (n = 58) – – –
Age group
  Adults ($18) 81.62 18.38 0.102
  child (,18) 74.50 25.50 –
Gender
  Male 46.84 53.16 0.670
  Female 36.69 63.31 –
Table 3 results of the multivariate logistic regression analysis
Variable Reference Odds ratio 95%  
Confidence   
interval
Age
  children (0–18 y) Adult 0.632 0.366–1.093
Race
  African Americans White 0.495 0.248–0.987
Gender
  Male Female 0.925 0.558–1.533
Ethnicity
  hispanic non-hispanic 1.482 0.668–3.289
State
  california Texas 0.718 0.401–1.286
  illinois Texas 0.934 0.497–1.755
  Alabama Texas 0.886 0.501–1.566
Annual income
  20,000–34,999 ,20,000 0.969 0.465–2.019
  35,000–54,999 ,20,000 1.304 0.636–2.670
  .55,000 ,20,000 1.039 0.545–1.983
Insurance status
  insured Uninsured 2.378 1.106–5.110
Asthma severity 
  Moderate Mild 1.145 0.591–2.218
  severe Mild 1.530 0.854–2.743Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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were found to have much lower odds of using ICSs when 
compared with majority whites. This difference was pres-
ent even after adjustments for other demographic factors. 
Racial and ethnic disparities in patients with asthma have 
gained attention and have been discussed earlier in   literature.2 
  Studies have shown disparities in asthma   outcomes, but less 
is known about disparities at the treatment level,   especifically 
the role that utilization of ICSs plays in improving asthma 
outcomes. Our study attempted to explore whether   disparities 
in controller medications may partly explain the overall 
disparities in asthma outcomes.
Several possible reasons have been discussed in the 
literature as a cause for these disparities. Two broad, under-
lying reasons that have been discussed are lack of access 
to care and inconsistencies in health-care treatment using 
NHLBI guidelines.6 Another cause may be the higher 
likelihood of alternative treatments in place of traditional 
medications in the African American population.14 Based 
on the evidence in literature and results seen in our own 
study, the need is   paramount to implement some sort of 
intervention   programs for minorities. An action agenda 
to eliminate asthma   disparities has identified that lack of 
cultural   competencies at many sites of asthma care do 
exist, and steps should be taken to bridge this critical gap 
in the future.15 Use of quality improvement   strategies and 
  improvement in   communication skills of the providers 
have also been suggested when   designing interventions for 
  minority populations.16 Past efforts have included programs 
such as the Multifamily Asthma Group Treatment (MFAGT), 
which aimed at   improving asthma management specifically 
in African Americans and Hispanics.17 This   small-scale study 
had managed to improve knowledge and decrease ER visits 
in the target population. Similar   interventions on larger scale 
can help in reducing the existing disparities as found in this 
study. By highlighting these disparities, the authors hope to 
build a case for urgent need for such intervention programs 
to help the vulnerable population.
Besides race, insurance status was also found to be a 
significant predictor for the use of ICSs. People with insur-
ance had a higher likelihood of using controller drugs than 
people without insurance. Insurance status has been linked 
to the utilization of necessary health-care services by many 
studies.6 With the new health-care reform bill, it is hoped 
that the number of uninsured patients with asthma will be 
reduced. Consequently, this will improve access to ICSs and 
eliminate disparities because of health insurance.
Poor adherence to ICSs is a growing issue in   managing 
asthma amongst the population with persistent asthma. 
Investigating disparities in use of ICSs provides important 
information about subpopulations that are vulnerable to 
nonadherence with ICSs. Results from this study help to 
point out such populations in a hope to direct policy makers 
to formulate specific strategies to diminish the disparities. 
The results also help to educate and inform health-care 
providers about the issue of underutilization of ICSs and 
existing disparities.
Limitations
The study has limitations that are both unique and   attributable 
to the large database nature of a retrospective study. The 
  survey used patients with asthma from 4 states only; 
  therefore, these findings cannot be generalized to the national 
population with asthma. The study is fairly generalizable 
to patients with asthma in these 4 states, which are highly 
populated and diverse in terms of patients with asthma. As the 
survey used self-reporting of data by the patient, it is likely to 
suffer from recall bias. As the survey was cross-sectional in 
nature, there was no way researchers can identify any causal 
effect. Further research needs to be done probing the cause of 
these disparities and why the underuse of ICSs continues to 
exist despite the existence of established treatment guidelines 
and recommendations.
Conclusion
The study confirmed the findings from existing literature 
about the underuse of ICSs among patients with   persistent 
asthma despite the strong recommendations from national 
guidelines. The study population also showed certain 
  disparities regarding reported use of ICSs. African   Americans 
and patients with no health insurance demonstrated a 
  disproportionally lower percentage of reported use of ICSs. 
Further research needs to be done probing the cause of 
these disparities and why the underuse of ICSs continues 
to exist.This study was successful in identifying vulner-
able   populations that can be targeted for the use of ICSs. 
The importance of adherence to treatment and use of ICSs 
is an issue that needs to be addressed.
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